Jack A. Khattar Sells 140,000 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Key Points

• Supernus Pharmaceuticals CEO Jack A. Khattar sold 140,000 shares of the company's stock for a total of $5,882,800, resulting in an 11.96% decrease in his holdings.
• The company's stock price fell by 0.6% on Friday, trading at $41.23 with a market cap of $2.31 billion.
• Equities research analysts have upgraded Supernus Pharmaceuticals, with Cantor Fitzgerald raising the price target from $42.00 to $46.00 and recommending an "overweight" rating.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack A. Khattar sold 140,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the completion of the transaction, the chief executive officer owned 1,030,183 shares in the company, valued at $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Supernus Pharmaceuticals Stock Performance

SUPN traded up $1.22 on Wednesday, hitting $42.46. 130,243 shares of the company were exchanged, compared to its average volume of 628,550. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $43.62. The company has a market cap of $2.38 billion, a PE ratio of 37.03 and a beta of 0.74. The stock's fifty day moving average is $33.78 and its 200-day moving average is $33.47.

Analyst Ratings Changes

Several research analysts have weighed in on SUPN shares. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC raised its stake in Supernus Pharmaceuticals by 7.4% in the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after buying an additional 360,000 shares during the period. Geode Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after purchasing an additional 28,517 shares during the period. GW&K Investment Management LLC increased its stake in shares of Supernus Pharmaceuticals by 14.6% during the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock worth $45,275,000 after purchasing an additional 176,091 shares during the period. Northern Trust Corp grew its position in Supernus Pharmaceuticals by 18.3% during the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after buying an additional 110,867 shares in the last quarter. Finally, Ashford Capital Management Inc. grew its position in Supernus Pharmaceuticals by 3.8% during the first quarter. Ashford Capital Management Inc. now owns 566,556 shares of the specialty pharmaceutical company's stock worth $18,555,000 after buying an additional 20,781 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.